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OBJECTIVE — Interest continues to grow regarding the therapeutic potential for umbilical
cord blood therapies to modulate autoimmune disease. We conducted an open-label phase I
study using autologous umbilical cord blood infusion to ameliorate type 1 diabetes.
RESEARCH DESIGN AND METHODS — Fifteen patients diagnosed with type 1 dia-
betesandforwhomautologousumbilicalcordbloodwasstoredunderwentasingleintravenous
infusion of autologous cells and completed 1 year of postinfusion follow-up. Intensive insulin
regimenswereusedtooptimizeglycemiccontrol.Metabolicandimmunologicassessmentswere
performed before infusion and at established time periods thereafter.
RESULTS — Median(interquartilerange[IQR])ageatinfusionwas5.25(3.1–7.3)years,with
amedianpostdiagnosistimetoinfusionof17.7(10.9–26.5)weeks.Noinfusion-relatedadverse
events were observed. Metabolic indexes 1 year postinfusion were peak C-peptide median 0.50
ng/ml (IQR 0.26–1.30), P  0.002; A1C 7.0% (IQR 6.5–7.7), P  0.97; and insulin dose 0.67
units   kg
1   day
1 (IQR 0.55–0.77), P  0.009. One year postinfusion, no changes were
observed in autoantibody titers, regulatory T-cell numbers, CD4-to-CD8 ratio, or other T-cell
phenotypes.
CONCLUSIONS — Autologous umbilical cord blood transfusion in children with type 1
diabetes is safe but has yet to demonstrate efﬁcacy in preserving C-peptide. Larger randomized
studies as well as 2-year postinfusion follow-up of this cohort are needed to determine whether
autologouscordblood–basedapproachescanbeusedtoslowthedeclineofendogenousinsulin
production in children with type 1 diabetes.
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T
ype 1 diabetes is an autoimmune dis-
order characterized by T-cell–
mediated destruction of insulin-
producing -cells and lifelong dependence
on exogenous insulin administration. To
date, the majority of efforts seeking to
amelioratetheautoimmuneprocessandre-
versehyperglycemiahavefocusedonthe
use of immunosuppressive or immuno-
modulatory drugs (1–4). Although sev-
eral agents have shown and continue to
show promise, no single agent has suc-
ceededindemonstratinglong-termsuc-
cess in preventing or reversing type 1
diabetes as a means of standard medical
practice. More recently, efforts have
focused on the use of either autologous
or allogeneic hematopoietic stem/
progenitor cells as potential immuno-
regulatoryagentstoreversethisdisease.
Whereas hematopoietic stem cells have
successfully been directed in vitro to
differentiate into insulin- and C-
peptide–producing cells (5), and infu-
sion of human hematopoietic stem cells
into diabetic animals has demonstrated
reversal of disease (6,7), the potential of
suchcellstoprovideasourceofsafeand
effective immunomodulation may be of
the greatest importance in treating type
1diabetes,butthishasyettoberealized
(8–10).
Among the broad array of potential
cell-based therapies, the use of autolo-
gous umbilical cord blood as a source of
immunomodulatory cells for the treat-
mentofautoimmunediseaseshasbecome
increasingly popular (11–14), this based
on the potential for umbilical cord blood
to restore proper immune regulation.
Umbilical cord blood contains a robust
population of immature unprimed highly
functional regulatory T-cells (Tregs) (15).
These highly functional Tregs could, in
theory, limit inﬂammatory cytokine re-
sponsesandanergizeeffectorT-cells,which
are thought to play a key role in cellular-
mediated autoimmune processes (16,17).
As such, umbilical cord blood Tregs have
become a major focus of our work in de-
signing cell-based therapies for children
with type 1 diabetes (18).
Practical matters provide an addi-
tional rationale for umbilical cord blood–
based therapies. First, the lack of low-risk
(i.e., safe) diabetes intervention trials
seeking to reverse disease, especially for
young children with type 1 diabetes, ren-
ders the potential use of umbilical cord
blood particularly appealing. Second, as
the rates of umbilical cord blood storage
continue to increase exponentially, the
number of potential subjects for autolo-
gous umbilical cord blood–based clinical
trials continues to grow. Third, the fact
thatumbilicalcordbloodisstoredatbirth
without need for additional intervention
(i.e., bone marrow biopsy or stem cell
mobilization and aphaeresis) is an addi-
tionalpracticaladvantageinconsideringa
cell-basedtherapyforchildren.Finally,as
umbilical cord blood storage facilities
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that would allow for multiple withdraw-
als, potential exists for protocols that in-
volve cell expansion and/or multiple cell
infusions.
Although we focused our interest on
the notion that umbilical cord blood
Tregs might affect tolerance, we also con-
sidered that autologous umbilical cord
blood transfusion in the setting of type 1
diabetes may help mitigate the autoim-
mune process by a variety of mechanisms
beyond those of direct immune modula-
tion(19).First,umbilicalcordbloodstem
cells may migrate to the damaged pan-
creas, where they could differentiate into
insulin-producing -cells (2). In addi-
tion, umbilical cord blood stem cells
might act as nurse cells to foster the pro-
liferation or replication of new -cells
from remnant viable tissue (20). Finally,
umbilical cord blood Tregs may facilitate
bystander suppression of effector T-cells,
allowing for the restoration of tolerance
by their inhibitory effects on multiple cell
types (21).
Based on available preclinical data
and the agreement that infusion of mini-
mally manipulated autologous umbilical
cordbloodwaslikelytobeextremelysafe,
we performed an unblinded observa-
tional pilot study to determine whether
autologous umbilical cord blood infusion
could impede the type 1 diabetes autoim-
muneprocessandpreserveremainingen-
dogenous insulin production. Peak
C-peptide after a standard mixed-meal
tolerancetest(MMTT),A1C,anddailyin-
sulin requirement were set as the primary
outcome variables, with a variety of im-
munologic markers assessed for their po-
tential mechanistic insights.
RESEARCH DESIGN AND
METHODS— A detailed description
ofthestudyprotocol’sdesign,withoutre-
sults,hasbeenpublishedpreviously(18).
The study timeline is displayed in Fig. 1.
Brieﬂy, subjects aged 1 year with type 1
diabetes (established by clinical presenta-
tion and presence of type 1 diabetes–
associated autoantibodies) and for whom
autologous umbilical cord blood had
beenstoredinanAmericanAssociationof
Blood Banks (AABB)- or Foundation for
the Accreditation for Cellular Therapy
(FACT)-recognized cord blood bank,
were recruited for participation in this
single-centerstudy(NCT00305344;FDA
IND BB-11918). This Federal Drug Ad-
ministration (FDA)-approved study of 23
subjects completed enrolment in Novem-
ber 2008. Follow-up for the entire cohort
will continue until all subjects have
reached the 2-year postinfusion study
visit. For this report, the ﬁrst 15 of these
23 subjects who completed at least 1 year
postinfusion follow-up are reported
herein. In addition, because the FDA and
institutional review board did not allow,
on this occasion, for the implementation
of a placebo-controlled investigation, for
comparative purposes we collected retro-
spective data on type 1 diabetic subjects
matched 2:1 (control subjects to umbili-
cal cord blood recipients) for age and du-
ration of disease.
After eligible subjects were identiﬁed
and provided consent, peripheral blood
and an aliquot of umbilical cord blood
from the subject were shipped to the Uni-
versity of Florida stem cell laboratory
where infectious disease testing, HLA
conﬁrmation, and screening for viability
were performed. Thereafter, the subject’s
remaining umbilical cord blood unit was
shipped to the University of Florida and
stored until transfused. Subjects were
then scheduled to perform a standard 2-h
MMTTtodeterminebaselineendogenous
insulin production and A1C values. Ad-
ditionalbloodwasdrawnforroutineclin-
ical assessments as well as metabolic and
immunologic analyses.
On the subsequent day, the subject’s
autologous umbilical cord blood was
thawed and washed per standard opera-
tion procedures of the University of Flor-
ida stem cell laboratory. An aliquot of
cellswasanalyzedforviability,CD34per-
centage, and Treg frequency (i.e., percent-
age of CD3CD4CD25FOXP3
cells). After the preparation of the unit,
subjects received pretreatment with di-
phenhydramine and acetaminophen. No
chemotherapy or other preparative ther-
apywasgiven.Thethawedumbilicalcord
bloodcells(typically100ml)werethen
infused through a peripheral intravenous
dripover10–20min.Afterinfusion,sub-
jects were observed closely for at least 6 h
prior to being discharged.
Subjects returned for follow-up test-
ing every 3 months in the ﬁrst postinfu-
sion year and every 6 months in the
second postinfusion year. MMTT, com-
plete blood count, basic metabolic panel,
and A1C were performed at each visit. In
addition, whole blood collected in EDTA
tubes was analyzed by ﬂow cytometry
with staining for the cell surface markers
CD3, CD4, CD8, and CD25 as well as the
intracellular marker FOXP3 using stan-
dard techniques (21–23). Throughout
the study, subjects were encouraged to
use any combination of available inten-
sive insulin regimens to achieve the best
Figure 1—Autologous cord blood infusion in type 1 diabetes: study timeline. Our study was designed as a 2-year observational study of the effects
ofautologouscordbloodinfusioninchildrenwithtype1diabetes.Eachchildwasfollowedevery3monthsduringtheﬁrstyearpostinfusionandevery
6monthsduringthesecondyearpostinfusion.Bloodwasobtainedformetabolicandimmunologicstudiesateachvisit.Meantimefromtype1diabetes
diagnosis to umbilical cord blood infusion was 6 months. Herein, we report 1 year postinfusion data on the ﬁrst 15 umbilical cord blood recipients
to reach 1 year of post–cord blood infusion follow-up. T1D, type 1 diabetes; UCB, umbilical cord blood; q, every.
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glycemic agents other than insulin or any
immunosuppressive agents was not
permitted.
Statistical analysis
Because of the propensity for outliers in
several of the outcome variables, medians
and quartiles were reported rather than
means and SDs. To determine changes
frombaselineto12months,wecalculated
the fractional change for each subject as
[(Y12/Y0)  1], where the subscript is the
month number. These fractional changes
were then tested for a target population
null hypothesis of a median of zero by the
two-sided Wilcoxon sign-rank test, a
nonparametric procedure. The pilot na-
tureofthisstudydictatedagainstcontrol-
ling study-wide errors via either a
Bonferroni correction or formal multivar-
iate analysis. Historical control compari-
sons used the two-sided two-sample
Wilcoxon test.
RESULTS— Between 24 August 2005
and21November2008,23childrenwith
type 1 diabetes (10 male and 13 female)
underwent a single autologous umbilical
cord blood transfusion at the University
of Florida. As of January 2009, 15 sub-
jects (7 male and 8 female) completed 1
year of postinfusion study follow-up.
Baseline and 1-year postinfusion charac-
teristics of these 15 subjects are provided
in Table 1.
Withtheexceptionofoneautologous
umbilical cord blood unit recovered from
a public bank, the remaining 22 units
werestoredinprivatecordbloodfacilities
throughout the U.S., Canada, and Mex-
ico. The median infused total nucleated
cell count in those subjects with 1 year of
follow-up was 1.50  10
7 cells/kg. Me-
dian viability was 96% (range 92–99%).
Overall, the total nucleated cell count re-
covered was commonly 1– to 2–log-fold
less than that typically observed in sam-
ples obtained from public banks (24).
All aliquots of umbilical cord blood
had negative gram stains, and none grew
pathogenic organisms when cultured for
virus, bacteria, or fungus. No adverse
events were observed in association with
autologous umbilical cord blood infu-
sion.Noneofthe23subjectsreceivingthe
cellular infusion developed fever, hypo-
or hypertension, nausea or vomiting, ab-
normalities in serum creatinine, or clini-
cally relevant changes in complete blood
count parameters. Furthermore, no sub-
jectreportedaseverehypoglycemicevent
(seizure or hypoglycemia requiring assis-
tance) or admission for treatment of dia-
betic ketoacidosis throughout the ﬁrst
year of follow-up.
In the 15 subjects with at least 1 year
of study follow-up (average 18 months
postdiagnosis), median peak C-peptide
(interquartile range [IQR]) at the time of
autologous umbilical cord blood infusion
was 0.93 (0.7–2.03 ng/ml). At the 1 year
post–umbilical cord blood infusion visit,
median peak C-peptide was 0.5 (0.26–
1.30 ng/ml). The fractional change in
peak C-peptide from infusion to 1 year
was 53% (P  0.0024). The fractional
change of area under the curve C-peptide
over the 1 year after umbilical cord blood
infusion was 69.4% (P  0.0007). For
the same group of study subjects, initial
median A1C was 7.0% and 1 year post–
umbilical cord blood infusion A1C was
7.0%. Median fractional change in A1C
was 0.035% (P  0.45). Initial median
insulin requirement was 0.42 units   kg
1  
day
1 with 1 year post–umbilical cord
blood insulin requirements of 0.67 units  
kg
1   day
1. The median fractional in-
crease in insulin requirement over 1 year
was 52% (P  0.0085).
Inordertofurtheridentifyapotential
clinical beneﬁt for this procedure, a com-
parativeanalysisofA1Candinsulinusein
this group of umbilical cord blood–
treatedsubjectsversusahistoricalcontrol
Table 2—Historical control subjects (n  30)
6 months postdiagnosis
18 months
postdiagnosis (Baseline-to–1 year ratio) 1
Median (IQR) P Median (IQR) Median (IQR) P
A1C (%) 7.6 (6.6–8.2) 0.16 7.8 (7.3–8.5) 0.040 (0.076 to 0.146) 0.73
Insulin use (units   kg
1   day
1) 0.56 (0.50–0.67) 0.011 0.77 (0.68 to 0.85) 0.41 (0.15–0.59) 0.50
Comparisonsweremadeusing6monthsand18monthspostdiagnosistimepointsbecausethesecorrelatedwithaveragetimefromdiagnosistoinfusionandaverage
time from diagnosis to 1 year postinfusion in the umbilical cord blood recipients. P values are by two-sided Wilcoxon tests vs. umbilical cord blood recipients. See
Table 1 for descriptive statistics for umbilical cord blood recipients.
Table 1—Baseline and 1-year postinfusion characteristics of autologous umbilical cord blood recipients (n  8 male and 7 female)
Preinfusion 1-year postinfusion
(Preinfusion-to–1 year
postinfusion ratio) 1 P vs. baseline
Age (years) 5.5 (3.1–7.3) — — —
Time from diagnosis to infusion (months) 4.1 (2.5–7.1) — — —
A1C (%) 7.0 (6.1–8.3) (15) 7.0 (6.5–7.7) (15) 0.035 (0.07 to 0.125) (15) 0.45
Insulin use (units   kg
1   day
1) 0.42 (0.21–0.55) (15) 0.67 (0.55–0.77) (15) 0.52 (0.00–1.56) (15) 0.0085
Peak C-peptide (ng/ml) 0.93 (0.7–2.03) (14) 0.50 (0.26–1.30) (12) 0.53 (0.72 to 0.32) (12) 0.0024
IA-2 9.5 (1.8–20.6) (11) 9.8 (0.7–14.47) (9) 0.48 (0.58 to 0.10) (8) 0.20
GAD 4.2 (0.9–11.4) (13) 3.5 (0.45–33.5) (12) 0.44 (0.63 to 0.34) (11) 0.52
WBC (cell  10
9/l) 5.5 (4.9–7.3) (14) 4.9 (4.2–6.3) (14) 0.13 (0.29 to 0.14) (14) 0.031
CD4-to-CD8 ratio 2.0 (1.7–2.6) (14) 1.9 (1.6–2.2) (12) 0.03 (0.13 to 0.11) (12) 0.86
Peripheral blood Treg (%) 5.4 (2.4–7.0) (12) 5.0 (4.1–7.2) (13) 0.31 (0.06 to 2.00) (11) 0.12
Data are median (IQR) (n). IA-2, insulinoma-associated protein 2 autoantibody; WBC, white blood cell count.
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also performed. Because the average time
from type 1 diabetes diagnosis to umbili-
cal cord blood infusion was 6 months,
comparisons were made between umbili-
cal cord blood recipients at 0, 6, and 12
months postinfusion and control subjects
at 6, 12, and 18 months post–type 1 dia-
betes diagnosis. In this group of control
subjects (mean age 5.28 years at diagno-
sis), median A1C and insulin use 18
months after diagnosis were 7.8 and
0.77% units   kg
1   day
1, respectively.
Umbilical cord blood recipients demon-
strated lower preinfusion insulin require-
ments (P  0.011) but similar A1C (P 
0.16) when compared with the historical
controlsubjects.WhereastheA1Cwas,as
noted earlier, stable over the 1 year of fol-
low-up in umbilical cord blood recipi-
ents, the percent change in A1C and
insulinusewerenotsigniﬁcantlydifferent
whencomparingumbilicalcordbloodre-
cipients and control subjects at the 12-
month follow-up visit (Table 2, Fig. 2A
and B). Fractional changes in A1C and
insulin requirement at 6 months postin-
fusionwerealsonotsigniﬁcantlydifferent
between umbilical cord blood recipients
and historical control subjects (data not
shown).
Primary analyses examined changes
in serum and peripheral blood immune
markersfromcordbloodinfusiontothe1
year postinfusion visit. Baseline and 12-
month median total peripheral white
blood cell count were 5.5  10
9 cells/l
and 4.9  10
9 cells/l, respectively, indic-
ative of a 12.9 fractional change (P 
0.03). Median and 12-month post-
infusion serum GAD antibody concentra-
tions were 4.2 units/ml and 3.5 units/ml,
respectively (P  0.52). Serum insuli-
noma-associated protein 2 autoantibody
at infusion and 12 months later were un-
changed at 9.5 units/ml and 9.8 units/ml,
respectively (P  0.20). CD4-to-CD8 ra-
tio was 1.98 at screening and 1.93 12
months after cord blood infusion (P 
0.85). CD4
CD25
FOXP3
 (Treg) per-
centages in peripheral blood at infusion
and after 12 months were 5.4 and 5.0%,
respectively (P  0.12) (Table 1). No
changes in peripheral blood CD45RA
(naïve) or CD45RO (memory) cells were
observed when comparing baseline and
12-month postinfusion data (data not
shown). Hypothesis-generating analysis
of the changes in peripheral blood Treg
concentration demonstrated a 42% frac-
tional increase of Treg during the 6
months immediately after cord blood in-
fusion(P0.06)withthemajorityofthat
increase occurring between the 3 and 6
months visits (fractional increase in Treg
35.6%; P  0.01). No changes in CD4-
to-CD8 ratio, CD45RA, or CD45RO cells
were seen when comparing data at infu-
sion, 3 months, or 6 months.
CONCLUSIONS— As the ﬁrst study
of a cell-based therapy in children with
type 1 diabetes, the most important and
robust observation our phase I study pro-
vides is that autologous umbilical cord
blood infusion in young children with
type 1 diabetes is feasible and safe. How-
ever, the potential efﬁcacy of autologous
umbilical cord blood infusion in the type
1 diabetes setting remains less clear. The
currently available data suggest that au-
tologous umbilical cord blood infusion
failstopreserveC-peptidelevelsinyoung
children1yearafterinfusion.Assuch,the
Figure 2—Insulin use (A) and A1C (B) in umbilical cord blood recipients and historical control
subjectsover1year.DataaremedianswitherrorbarsshowingIQRsandarepresentedforthesake
of comparison with clinical expectations. Because the average time from diagnosis to umbilical
cord blood infusion was 6 months, comparisons correlate with 6, 12, and 18 months post–type 1
diabetesdiagnosisinbothumbilicalcordbloodrecipientsandhistoricalcontrolsubjects.Whereas
the absolute value of A1C and insulin requirement in umbilical cord blood recipients was lower
than that in control subjects at baseline, 6 months, and 12 months, the relevant statistical com-
parison of percent change was no different over time (Table 2).
Cord blood infusion in type 1 diabetes
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23-subjectcohortofumbilicalcordblood
recipients will be important in more con-
clusively documenting the efﬁcacy of au-
tologous umbilical cord blood infusion in
type 1 diabetes.
BecauseneithertheFDAnorourlocal
institutional review board would allow
for a randomized or blinded study, we
were unable to perform age-matched
comparisons of meal-stimulated endoge-
nous insulin production. Furthermore,
the lack of comparative meal-stimulated
C-peptide data in young children with
type 1 diabetes made historical compari-
sons impossible. Comparison to an age-
matched group of type 1 diabetic patients
demonstrated that subjects receiving um-
bilical cord blood infusion maintained A1C
and insulin requirements below what most
clinicians would expect in such young chil-
dren. Nevertheless, among umbilical cord
blood recipients, peak and area under
the curve C-peptide levels 1 year post–
umbilical cord blood infusion declined sig-
niﬁcantly when compared with baseline
and fractional changes in A1C, and insulin
requirement were no different when com-
paring umbilical cord blood recipients and
historical control subjects.
As we further explore potential appli-
cations of autologous umbilical cord
bloodintreatingtype1diabetes,practical
considerations will continue to drive our
approach. Notably, the cell counts recov-
ered from privately banked cord blood
units used in our study were routinely an
orderofmagnitudelowerthancellcounts
from publicly banked units prepared us-
ing the same techniques. This should not
necessarily impugn private cord blood
banks for providing substandard storage
but more likely reﬂects the frequency of
low cell counts at collection and explains
whypublicbankscollectandthendiscard
a large percentage of donated units. The
relatively low cell counts used in this
phase I study may indicate that much
higher cell counts are needed to induce
relevant immunologic or metabolic ef-
fects.Additionaleffortstoimprovecollec-
tion, storage (i.e., multiple aliquots), cell
recovery,andexpansionofumbilicalcord
bloodareurgentlyneededtoallowforthe
development of additional applications
beyond traditional umbilical cord blood
transplantation.
Additionally, the dictum of primum
non nocere must remain paramount
when discussing interventional therapies
for young children with type 1 diabetes.
The development of both safe and effec-
tive therapies to preserve -cell function
in patients with type 1 diabetes presents a
formidable catch-22. Although high-
potency immunosuppressive and immu-
nomodulatory cocktails may indeed be
able to preserve C-peptide levels in re-
cently diagnosed patients (14), such ap-
proachesareassociatedwithconsiderable
risk of morbidity and even mortality.
Type 1 diabetes is inarguably a disease
with substantial short-term and long-
termcomplications.Nevertheless,insulin
is fairly effective, albeit a cumbersome
and imperfect therapy. Our group has
long espoused the need to use combina-
tionapproachesmuchlikethosethathave
proven effective in treating cancer or HIV
(25). Still, we must recall that type 1 dia-
betes is neither cancer nor HIV. Potential
combination approaches, including those
that include cell therapy, should be asso-
ciated with appropriately low risk pro-
ﬁles, especially when being considered
for use in children.
The potential of umbilical cord blood
to participate in the future of type 1 dia-
betesinterventionaltherapiesexists.Nev-
ertheless, multiple therapeutic avenues
will need to be explored, and several mo-
dalities will likely need to be combined to
achieve the dream of safely and perma-
nently reversing or preventing type 1 di-
abetes. Future efforts to use autologous
umbilical cord blood in the treatment of
type1diabeteswillcontinuewithempha-
sis on mechanistic studies, establishment
of age-appropriate comparative groups,
and addition of multiple safe therapies
(i.e., vitamin D and n-3 fatty acids) in
hopes of achieving synergy.
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